7. The bispecific antibody according to any one of claim 5 or 6, wherein the constant heavy chain region of IgG1 subclass further comprises the mutations L234A , L235A and P329G (numbering according to EU Index of Kabat)

8. A pharmaceutical composition comprising an antibody according to any one of claims 5 to 7.

9. The bispecific antibody according to any one of claims 5 to 7 for use in the treatment of ocular vascular diseases.

10. The bispecific antibody according to claim 9, wherein the antibody is to be administered via intravitreal application.

11. A nucleic acid encoding a bispecific antibody according to any one of claims 5 to 7.

12. Expression vector containing said nucleic acid according claim 11 capable of expressing said nucleic acid in a prokaryotic or eukaryotic host cell.

13. A prokaryotic or eukaryotic host cell comprising a vector according to claim 12.

14. A method for the preparation of a bispecific antibody according to any one of claims 5 to 7

comprising the steps of

a) transforming a host cell with vectors comprising nucleic acid molecules encoding said antibody;

b) culturing the host cell under conditions that allow synthesis of said antibody molecule; and

c) recovering said antibody molecule from said culture.

15. A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, characterized in comprising the amino acid sequences of SEQ ID NO: 25, of SEQ ID NO: 26, of SEQ ID NO: 27, and of SEQ ID NO: 28.

16. A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, characterized in comprising the amino acid sequences of SEQ ID NO: 21, of SEQ ID NO: 22., of SEQ ID NO: 23., and of SEQ ID NO: 24.

17. The bispecific antibody according to any one of claims 15 or 16 for use in the treatment of ocular vascular diseases.

18. The bispecific antibody according to claim 17, wherein the antibody is to be administered via intravitreal application.

19. Use of the bispecific antibody according to any one of claims 5 to 7, 15 or 16 in the manufacture of a medicament for the treatment of ocular vascular diseases.

20. Use of claim 19, wherein the antibody is to be administered via intravitreal application.